Supply Chain Intelligence

Lexeo Therapeutics, Inc. Supply Chain

LXEO supply chain intelligence for Lexeo Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

LXEO ·Last updated 2026-09-13 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

16Suppliers
25Customers
3Debt Items
20Related Chains

Source-Backed Evidence Depth

Lexeo Therapeutics, Inc. (LXEO) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

45Total relationships
3Distinct source URLs
8High confidence
0.730Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Lexeo Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
THE-REGENTS-OF-UNIVERSITY-OF-CALIFORNIA-SAN-DIEG THE-REGENTS-OF-UNIVERSITY-OF-CALIFORNIA-SAN-DIEG 92% we obtained a license to materials and intellectual property related to a gene therapy for ARVC
STELIOS-THERAPEUTICS-INC STELIOS-THERAPEUTICS-INC 90% The Company is required to pay up to a remaining aggregate of $ 12.5 million to the selling shareholders of Stelios upon the achievement of certain development milestones
DSGN Design Therapeutics, Inc. 72% Reciprocal relationship from DSGN graph: Reciprocal relationship from LXEO graph: ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a…
DSGN Design Therapeutics, Inc. 72% ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on t…
LRMR Larimar Therapeutics, Inc. 72% Reciprocal relationship from LRMR graph: Reciprocal relationship from LXEO graph: ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a…
LRMR Larimar Therapeutics, Inc. 72% ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on t…
NBIX Neurocrine Biosciences, Inc. 72% Reciprocal relationship from NBIX graph: Reciprocal relationship from LXEO graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from LXEO graph: ply, if any, could be identified an…
NBIX Neurocrine Biosciences, Inc. 72% ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on t…
PRME Prime Medicine, Inc. 72% ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on t…
PRME Prime Medicine, Inc. 72% Reciprocal relationship from PRME graph: Reciprocal relationship from LXEO graph: ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a…
PTCT PTC Therapeutics, Inc. 72% Reciprocal relationship from PTCT graph: Reciprocal relationship from LXEO graph: ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a…
PTCT PTC Therapeutics, Inc. 72% ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on t…
SLDB Solid Biosciences Inc. 72% Reciprocal relationship from SLDB graph: Reciprocal relationship from LXEO graph: Reciprocal relationship from SLDB graph: Reciprocal relationship from LXEO graph: ply, if any, could be identified an…
SLDB Solid Biosciences Inc. 72% ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on t…
VYGR Voyager Therapeutics, Inc. 72% Reciprocal relationship from VYGR graph: Reciprocal relationship from LXEO graph: ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a…
VYGR Voyager Therapeutics, Inc. 72% ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on t…

Lexeo Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
CORNELL-LICENSE-AGREEMENTS-STELIOS-THERAPEUTICS- CORNELL-LICENSE-AGREEMENTS-STELIOS-THERAPEUTICS- 85% pect to the right of reference, or the licensed data, know-how, or patent rights, with 90 days’ prior written notice to Cornell. On December 17, 2025, the Company executed a Second Amendment to the T…
SPACECRAFT-SEVEN-LLC SPACECRAFT-SEVEN-LLC 85% dants downloaded confidential Rocket company documents and other proprietary materials prior to leaving Rocket in 2021 and that the Company used this information to advance its programs after they be…
DSGN Design Therapeutics, Inc. 72% Reciprocal relationship from DSGN graph: Reciprocal relationship from LXEO graph: Reciprocal relationship from DSGN graph: Reciprocal relationship from LXEO graph: Reciprocal relationship from DSGN g…
DSGN Design Therapeutics, Inc. 72% s, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays in doing so, our business will be materially harmed. We have invested a significan…
LRMR Larimar Therapeutics, Inc. 72% Reciprocal relationship from LRMR graph: Reciprocal relationship from LXEO graph: Reciprocal relationship from LRMR graph: Reciprocal relationship from LXEO graph: Reciprocal relationship from LRMR g…
LRMR Larimar Therapeutics, Inc. 72% s, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays in doing so, our business will be materially harmed. We have invested a significan…
NBIX Neurocrine Biosciences, Inc. 72% Reciprocal relationship from NBIX graph: Reciprocal relationship from LXEO graph: s, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays …
NBIX Neurocrine Biosciences, Inc. 72% s, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays in doing so, our business will be materially harmed. We have invested a significan…
PRME Prime Medicine, Inc. 72% Reciprocal relationship from PRME graph: Reciprocal relationship from LXEO graph: Reciprocal relationship from PRME graph: Reciprocal relationship from LXEO graph: Reciprocal relationship from PRME g…
PRME Prime Medicine, Inc. 72% s, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays in doing so, our business will be materially harmed. We have invested a significan…
PTCT PTC Therapeutics, Inc. 72% Reciprocal relationship from PTCT graph: Reciprocal relationship from LXEO graph: Reciprocal relationship from PTCT graph: Reciprocal relationship from LXEO graph: s, obtain marketing approval and ul…
PTCT PTC Therapeutics, Inc. 72% s, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays in doing so, our business will be materially harmed. We have invested a significan…
SLDB Solid Biosciences Inc. 72% s, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays in doing so, our business will be materially harmed. We have invested a significan…
SLDB Solid Biosciences Inc. 72% Reciprocal relationship from SLDB graph: Reciprocal relationship from LXEO graph: Reciprocal relationship from SLDB graph: Reciprocal relationship from LXEO graph: s, obtain marketing approval and ul…
VYGR Voyager Therapeutics, Inc. 72% Reciprocal relationship from VYGR graph: Reciprocal relationship from LXEO graph: Reciprocal relationship from VYGR graph: Reciprocal relationship from LXEO graph: Reciprocal relationship from VYGR g…
VYGR Voyager Therapeutics, Inc. 72% s, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays in doing so, our business will be materially harmed. We have invested a significan…
ADVERUM-BIOTECHNOLOGIES-INC ADVERUM-BIOTECHNOLOGIES-INC 62% dants downloaded confidential Rocket company documents and other proprietary materials prior to leaving Rocket in 2021 and that the Company used this information to advance its programs after they be…
AMENDED-CORNELL-LICENSE-AGREEMENTS-STELIOS-THERA AMENDED-CORNELL-LICENSE-AGREEMENTS-STELIOS-THERA 62% nell License Agreement, in whole or in part with respect to the right of reference, or the licensed data, know-how, or patent rights, with 90 days’ prior written notice to Cornell. On December 17, 20…
DELAWARE-GENERAL-CORPORATION DELAWARE-GENERAL-CORPORATION 62% ependent contractors have been incorrectly classified, the possibility nevertheless exists that certain contractors could be deemed to be employees. We are exposed to the risk that our employees, ind…
FDA-REATA-PHARMACEUTICALS-INC FDA-REATA-PHARMACEUTICALS-INC 62% ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on t…
IN-CATALYST-PHARMS-INC IN-CATALYST-PHARMS-INC 62% s, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays in doing so, our business will be materially harmed. We have invested a significan…
LEERINK-PARTNERS-LLC LEERINK-PARTNERS-LLC 62% and 3.6 years, respectively. The components of this operating lease were as follows: Three Months Ended March 31, 2026 2025 Operating lease expense $ 537 $ 537 Variable lease expense 131 126 Total op…
REATA-PHARMACEUTICALS-INC REATA-PHARMACEUTICALS-INC 62% ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on t…
STELIOS-THERAPEUTICS-INC STELIOS-THERAPEUTICS-INC 62% nell License Agreement, in whole or in part with respect to the right of reference, or the licensed data, know-how, or patent rights, with 90 days’ prior written notice to Cornell. On December 17, 20…
TILIA-THERAPEUTICS-INC TILIA-THERAPEUTICS-INC 62% ontinuing operations, if at all. 6 Risks and Uncertainties —The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not lim…

Lexeo Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
LXEO-DEBT-10838 Xbrl Convertible 90% xbrl convertible detail from xbrl 2023-12-31.
LXEO-DEBT Debt stack $7.4M 90% Market cache reports total debt of $7.4M.
LXEO-DEBT-59476 Warrants outstanding: 2446000 90% xbrl warrant detail from xbrl 2026-03-31.

Lexeo Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Lexeo Therapeutics, Inc..

Lexeo Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
LXEO-OWNER-JANUS-HENDERSON-GROUP-PLC JANUS HENDERSON GROUP PLC 90% 13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 139 tracked holders.

Lexeo Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
SLNO Soleno Therapeutics, Inc. 100.00 2
PRME Prime Medicine, Inc. 100.00 1 ['customer', 'supplier']
MGTX MeiraGTx Holdings plc 100.00 2
RNA Atrium Therapeutics, Inc. 100.00 2
SNYNF Sanofi 100.00 2
INSM Insmed Incorporated 100.00 2
NBIX Neurocrine Biosciences, Inc. 100.00 1 ['customer', 'supplier']
SRPT Sarepta Therapeutics, Inc. 100.00 2
STQN Strategic Acquisitions, Inc. 100.00 2
DSGN Design Therapeutics, Inc. 100.00 1 ['customer', 'supplier']
CLPT ClearPoint Neuro, Inc. 100.00 2
MPLT MapLight Therapeutics, Inc. 100.00 2
RARE Ultragenyx Pharmaceutical Inc. 100.00 2
ALEC Alector, Inc. 100.00 2
TKPHF Takeda Pharmaceutical Company Limited 100.00 2
TRDA Entrada Therapeutics, Inc. 100.00 2
AARD Aardvark Therapeutics, Inc. 100.00 2
MYGN Myriad Genetics, Inc. 100.00 2
ETON Eton Pharmaceuticals, Inc. 100.00 2
VYGR Voyager Therapeutics, Inc. 100.00 1 ['customer', 'supplier']
Browse supply chain intel →

See the full supply chain map, all relationships, and real-time alerts for Lexeo Therapeutics, Inc..

Unlock full LXEO data — View plans →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map
🔐
LXEO
Unlock LXEO Supply Chain Data
Verified relationships include:
THE-REGENTS-OF-UNIVERSITY-OF-CALIFORNIA-SAN-DIEGTHE-REGENTS-OF-UNIVERSITY…Supplier92%
STELIOS-THERAPEUTICS-INCSTELIOS-THERAPEUTICS-INCSupplier90%
CORNELL-LICENSE-AGREEMENTS-STELIOS-THERAPEUTICS-CORNELL-LICENSE-AGREEMENT…Customer85%
SPACECRAFT-SEVEN-LLCSPACECRAFT-SEVEN-LLCCustomer85%
+41 more relationships locked
Subscribe — View plans →
Already a subscriber? Sign in →